Actinic Keratosis https://greenmedinfo.com/taxonomy/term/503/all en A case report of successful treatment of actinic keratosis with kanuka honey. https://greenmedinfo.com/article/case-report-successful-treatment-actinic-keratosis-kanuka-honey PMID:  Case Rep Dermatol Med. 2018 ;2018:4628971. Epub 2018 May 31. PMID: 29955399 Abstract Title:  Successful Treatment of Actinic Keratosis with Kanuka Honey. Abstract:  Actinic keratoses form as rough, scaly plaques on sun-exposed areas; they can be an important step in premalignant progression to squamous cell cancer of the skin. Currently, pharmacological treatments consist of topical immunomodulatory agents with poor side effect profiles. Use of honey has been common in both ancient and modern medicine, where it is now a key therapy in the management of wound healing. In vitro studies show the New Zealand native Kanuka honey to have immunomodulatory and antimitotic effects, with recent evidence suggesting efficacy of topical application in a variety of dermatological contexts, including rosacea and psoriasis. Here, we present a case report of a 66-year-old gentleman with an actinic keratosis on his hand, which had been present for years. Regular application of Kanuka honey over three months resulted in remission immediately following the treatment period with no signs of recurrence at nine months. <p><a href="https://greenmedinfo.com/article/case-report-successful-treatment-actinic-keratosis-kanuka-honey" target="_blank">read more</a></p> https://greenmedinfo.com/article/case-report-successful-treatment-actinic-keratosis-kanuka-honey#comments Actinic Keratosis Kanuka Honey Immunomodulatory Human: Case Report Mon, 09 Jul 2018 15:47:37 +0000 greenmedinfo 167036 at https://greenmedinfo.com A low-fat diet reduces the incidence of actinic keratosis in patients with a history of nonmelanoma skin cancer. https://greenmedinfo.com/article/low-fat-diet-reduces-incidence-actinic-keratosis-patients-history-nonmelanoma- PMID:  N Engl J Med. 1994 May 5;330(18):1272-5. PMID: 8145782 Abstract Title:  Effect of a low-fat diet on the incidence of actinic keratosis. Abstract:  BACKGROUND. Actinic keratoses are premalignant lesions and are a sensitive and important manifestation of sun-induced skin damage. Studies in animals have shown that dietary fat influences the incidence of sun-induced skin cancer, but the effect of diet on the incidence of actinic keratosis in humans is not known. METHODS. We randomly assigned 76 patients with nonmelanoma skin cancer either to continue their usual diet (control group) or to eat a diet with 20 percent of total caloric intake as fat (dietary-intervention group). For 24 months, the patients were examined for the presence of new actinic keratoses by physicians unaware of their assigned diets. RESULTS. At base line, the mean (+/- SD) percentage of caloric intake as fat was 40 +/- 4 percent in the control group and 39 +/- 3 percent in the dietary-intervention group. After 4 months of dietary therapy the percentage of calories as fat had decreased to 21 percent in the dietary-intervention group, and it remained below this level throughout the 24-month study period. The percentage of calories as fat in the control group did not fall below 36 percent at any time. The cumulative number of new actinic keratoses per patient from months 4 through 24 was 10 +/- 13 in the control group and 3 +/- 7 in the dietary-intervention group (P = 0.001). CONCLUSIONS. In patients with a history of nonmelanoma skin cancer, a low-fat diet reduces the incidence of actinic keratosis. https://greenmedinfo.com/article/low-fat-diet-reduces-incidence-actinic-keratosis-patients-history-nonmelanoma-#comments Actinic Keratosis Dietary Modification: Low Fat Diet Human Study Wed, 09 Dec 2009 03:43:51 +0000 greenmedinfo 48197 at https://greenmedinfo.com Astragalin attenuates UVB radiation-induced actinic keratosis formation. https://greenmedinfo.com/article/astragalin-attenuates-uvb-radiation-induced-actinic-keratosis-formation PMID:  Anticancer Agents Med Chem. 2018 ;18(7):1001-1008. PMID: 29298652 Abstract Title:  Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation. Abstract:  BACKGROUND: Actinic Keratosis (AK), is the most common precancerous skin lesion induced by the excessive Ultraviolet B (UVB) and is a significant threat to the public health. UVB exposure causes oxidative DNA damage and is considered to be a significant contributor to AK and subsequent development of skin cancer. Besides, activation of p38 MAPK also plays a significant role in the development of AK.OBJECTIVE: This study aimed at the development of a nature compound which can inhibit UVB-induced AK.METHOD: MTS Cell Proliferation Assay Kit was used to detect the toxicity of astragalin. HE-staining, Immunohistochemical, Western blot and Enzyme Linked Immunosorbent Assay were applied to examine the clinicopathologic feature of AK and the change of p38 MAPK signal pathway treated with astraglin under the condition of UVB in vitro and in vivo. Results:In our clinical findings revealed that p38 MAPK, phospho-MSK1, and γ -H2AX were significantly highly expressed in human AK tissue than the normal healthy skin tissue. Moreover, in vitro studies showed that UVB induced the phospho-MSK1 and γ-H2AX in a time- and dose-dependent manner in HaCaT cells. Further, in vitro kinase assay demonstrated that astragalin could directly bind to p38 MAPK and suppress p38 MAPK activity. Furthermore, astragalin exhibited no toxicity and suppressed the UVB-induced expression of phospho- MSK1 and γ -H2AX by suppressing p38 MAPK activity in a time-dependent and dose-dependent manner in HaCaT cells. The in vivo studies with animal UV model demonstrated that astragalin inhibited UVB-induced expression of phospho-MSK1 and γ-H2AX in Babl/c mice.CONCLUSION: These results suggested that p38 MAPK is a direct valid molecular target of astragalin for the attenuation of UVB-induced AK. Furthermore, astragalin could be a potential promising novel natural therapeutic agent for the prevention and management of UVB-induced AK with high target specificity and low toxicity. <p><a href="https://greenmedinfo.com/article/astragalin-attenuates-uvb-radiation-induced-actinic-keratosis-formation" target="_blank">read more</a></p> https://greenmedinfo.com/article/astragalin-attenuates-uvb-radiation-induced-actinic-keratosis-formation#comments Actinic Keratosis Flavonoids Ultraviolet Radiation Induced Damage Photoprotective Sunlight exposure Risk Reduction In Vitro Study Sat, 28 Nov 2020 00:12:13 +0000 greenmedinfo 230317 at https://greenmedinfo.com Euphorbia peplus contains a compound that is efficacious in the treatment of actinic keratosis. https://greenmedinfo.com/article/euphorbia-peplus-contains-compound-efficacious-treatment-actinic-keratosis PMID:  Invest New Drugs. 2010 Dec;28(6):766-82. PMID: 19178487 Abstract Title:  PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Abstract:  The sap of the plant Euphorbia peplus is a traditional remedy for skin conditions, including actinic keratosis. The active constituent of the sap is ingenol mebutate (ingenol-3-angelate), formerly known as PEP005. This randomized, double-blind, vehicle-controlled, phase IIa study investigated the safety (and secondarily the efficacy) of two applications of ingenol mebutate gel in 58 patients with biopsy-confirmed actinic keratosis. Five preselected lesions were treated with ingenol mebutate gel, 0.0025%, 0.01% or 0.05%, or vehicle gel, on days 1 and 2 (Arm A) or days 1 and 8 (Arm B). There were no significant differences in tolerability or efficacy between Arms A and B. Treatment was well tolerated. The most common local skin responses were dose-related erythema, flaking/scaling/dryness and scabbing/crusting. Efficacy was greatest with ingenol mebutate gel, 0.05%, which resulted in complete clinical clearance of 71% of treated lesions (P &lt; 0.0001 vs vehicle gel). In addition, 67% of patients treated with ingenol mebutate gel, 0.05% had clinical clearance of at least four of five treated lesions (P = 0.0185 vs vehicle gel). Ingenol mebutate gel is being developed as a short-course topical therapy for actinic keratosis and non-melanoma skin cancer. https://greenmedinfo.com/article/euphorbia-peplus-contains-compound-efficacious-treatment-actinic-keratosis#comments Actinic Keratosis Euphorbia peplus Human Study Mon, 18 May 2009 12:42:44 +0000 greenmedinfo 44332 at https://greenmedinfo.com Plasma antioxidants are decreased in Actinic Keratosis and Basal Cell Carcinoma, indicating the potential therapeutic role of antioxidant supplementation. https://greenmedinfo.com/article/plasma-antioxidants-are-decreased-actinic-keratosis-and-basal-cell-carcinoma-i PMID:  J Eur Acad Dermatol Venereol. 1999 Sep;13(2):96-101. PMID: 10568487 Abstract Title:  Plasma antioxidant defense in actinic keratosis and basal cell carcinoma. Abstract:  BACKGROUND: Reactive oxygen species and lipid peroxides have been implicated in the pathogenesis of a variety of diseases, particularly cancer. There may be an inverse correlation between lipid peroxidation and antioxidant defense mechanisms. The aim of this study was to investigate whether certain plasma antioxidants (ascorbic acid, alpha-tocopherol, total thiol groups, ceruloplasmin, urate, albumin and erythrocyte glutathione) are altered in actinic keratosis (AK) and basal cell carcinoma (BCC). METHODS: Plasma samples and red blood cells (RBC) of 13 patients with AK, 12 with BCC and 16 healthy controls were investigated. RESULTS: Data analysis indicates significant decrease of ascorbic acid (P &lt; 0.001), alpha-tocopherol (P &lt; 0.05 and P &lt; 0.001), total thiol groups (P &lt; 0.001), ceruloplasmin (P &lt; 0.001 and P &lt; 0.05), and RBC glutathione (P &lt; 0.05) values in both AK and BCC groups compared to controls. Comparison of AK and BCC groups evidenced a significant decrease of alpha-tocopherol and RBC glutathione (P &lt; 0.05) in BCC patient. CONCLUSION: Plasma antioxidants are decreased in the AK and BCC, probably due to the long exposure to UV irradiation which is one of the most important factors in the etiology of AK and BCC and alpha-tocopherol and RBC glutathione (P &lt; 0.05) are most altered in BCC. https://greenmedinfo.com/article/plasma-antioxidants-are-decreased-actinic-keratosis-and-basal-cell-carcinoma-i#comments Actinic Keratosis Basal Cell Carcinoma Basal Cell Nevus Syndrome Mon, 20 Apr 2009 06:14:10 +0000 greenmedinfo 42637 at https://greenmedinfo.com St. John's Wort in combination with photodynamic therapy demonstrates therapeutic effects in Actinic Keratosis, Basal Cell Carcinoma and Bowen's disease. https://greenmedinfo.com/article/st-johns-wort-combination-photodynamic-therapy-demonstrates-therapeutic-effect PMID:  Photochem Photobiol. 2008 May-Jun;84(3):779-85. Epub 2008 Jan 7 PMID: 18179625 Abstract Title:  Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study. Abstract:  Hypericin, the photoactive compound of Hypericum perforatum, is probably the most powerful photosensitizer found in nature. This compound has shown high potency in the photodynamic treatment of tumor cells. However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells. The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ). The study was carried out on 34 patients--eight with actinic keratoses (AKs), 21 with BCC and five with Bowen&#039;s disease. The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm(-2) of red light 2 h later. The treatment was performed weekly for 6 weeks on average. The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen&#039;s disease. There was only a partial remission seen in patients with nodular BCCs. A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen&#039;s disease. All patients complained of burning and pain sensations during irradiation. Although the results of this first clinical trial could be regarded as disappointing, there are still possibilities for improvement. Better preparation of the lesions, enhancement of hypericin delivery and other types of light exposure procedures could significantly improve the clinical outcomes of this relatively inexpensive treatment modality. https://greenmedinfo.com/article/st-johns-wort-combination-photodynamic-therapy-demonstrates-therapeutic-effect#comments Actinic Keratosis Basal Cell Carcinoma Bowen's Disease St. Johns Wort Human Study Sun, 26 Apr 2009 16:28:00 +0000 greenmedinfo 43998 at https://greenmedinfo.com